Cencora, Inc. is expected to release its Q2 2026 10-Q filing in the upcoming earnings season. Last quarter: COR delivered strong Q2 FY2026 results with revenue rising 3.8% YoY to $78.4B, gross profit surging 17.3% to $3.6B, and net income more than doubling (+128.6%) to $1.6B, though year-to-date operating cash flow turned negative at -$967M amid elevated capital deployment.
Drawn from management commentary in the Q1 2026 10-Q:
COR grew revenue 3.8% YoY to $78.4B in Q2 FY2026, reflecting continued volume expansion in its pharmaceutical distribution and healthcare services segments. The growth rate, while moderate in absolute percentage terms, represents significant dollar-volume gains given the company's massive revenue base.
Gross profit jumped 17.3% YoY to $3.59B, pushing gross margin from 4.06% to 4.58%. This outpaced revenue growth substantially, suggesting favorable product/service mix shifts, improved specialty pharmaceutical contributions, or better contract terms with suppliers and customers.
Net income surged 128.6% YoY to $1.64B, far exceeding the 10.3% growth in operating income ($1.14B). The large divergence between operating income growth and net income growth implies significant below-the-line items — such as investment gains, tax benefits, or other non-operating income — contributed materially to the bottom line.
Revenue
$78.36B
++3.85% YoY
EPS (Basic)
$8.44
++128.11% YoY
Gross Margin
4.6%
++0.52% YoY
Operating Income
$1.14B
++10.27% YoY
Add COR to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.